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Up to 20% of cases of bullous pemphigoid (BP)
show an atypical presentation, exhibiting localized
distribution or non-bullous lesions, such as
eczematous, urticarial, prurigolike, and erythema
multiformelike papules and plaques.1 These atypical
presentations can be associated with a delay in
diagnosis and thus require a high degree of
suspicion. We present a case of recalcitrant BP
localized to the anogenital region with subsequent
generalization after administration of etanercept, a
tumor necrosis factorealpha (TNF-a) inhibitor. Our
review of bibliographic databases did not find any
cases with similar distribution and course. TNF-a
inhibitors are used in the treatment of pemphigus
and pemphigoid. With expanding use of TNF-a
inhibitors and longer follow-up periods, there are
increasing reports of autoimmune diseases associ-
ated with these therapies, including autoimmune
bullous disease and systemic lupus erythematosus.2
This case highlights that caution should be exercised
when considering antieTNF-a therapy for auto-
immune bullous diseases.CASE REPORT
A 79-year-old white woman with a history
of psoriasis and diabetes type 2 presented with
recalcitrant, perianal/perineal, and perivaginal
inflammatory erosions that were unresponsive to
potent topical corticosteroids (Fig 1). Biopsy found
lichenoid interface dermatitis with eosinophils and a
subepidermal cleft. Direct immunofluorescence
results (DIF) were negative. The histopathologicn University Department of Dermatologya and StrataDx.b
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sensitivity reaction, lichenoid contact dermatitis, and
a primary immunobullous disorder, likely BP.
Laboratory testing found normal serology findings,
with the exception of mild eosinophilia (0.67 K/L;
normal, \0.45 K/L), and a normal urinalysis
result. The eruption did not respond to courses of
hydroxychloroquine, mycophenolate mofetil, and
oral antibiotics or narrowband ultraviolet light B
and aminolevulinic acid photodynamic therapy. Oral
corticosteroid tapers provided only temporary
benefit, and diabetes was a contraindication to
longer systemic steroid treatment.
Lesions remained relatively stable for 16 months,
and at that time etanercept was administered for a
psoriasis flare. Within 3 days of starting etanercept,
the patient had generalized, pruritic, urticarial, and
bullous lesions (Fig 2). Biopsy of a bullous lesion on
the left upper thigh found a subepidermal blister
with eosinophils (Fig 3). DIF of perilesional skin of
both the right arm and perianal area found linear C3
and IgG at the dermaleepidermal junction (Fig 4).
There was no IgA or IgM deposition. A salt-split skin
immunofluorescence study on the perianal
specimen found IgG and C3 localized to the blister
roof, confirming the diagnosis of BP and ruling out
epidermolysis bullosa acquisita. The patient wasJAAD Case Reports 2016;2:25-7.
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Fig 1. Large, confluent erosions in the perianal/perineal
area and midgluteal fold.
Fig 2. Generalized pruritic, urticarial and bullous lesions
developed immediately after starting etanercept.
Fig 3. Biopsy section of a bullous lesion on the left upper
thigh shows a subepidermal blister with prominent
eosinophils. (Hematoxylin-eosin stain; original magnifica-
tion, 3200).
Fig 4. DIF: linear C3 deposition at the dermaleepidermal
junction. (Original magnification, 3100).
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formation ceasing 3 weeks into dapsone treatment at
100 mg/d. The lesions and pruritus further improved
at a dapsone dose of 150 mg/d.
DISCUSSION
Localized BP is uncommon and requires a high
index of suspicion.1 There are rare reports of
pediatric genital BP and 1 report of perineal/perianal
BP in an adult.3,4 Adult BP localized to both perianal/
perineal and perivaginal areas, such as that seen in
our patient, is an exceedingly rare presentation. The
differential diagnosis of BP localized to the genital
and perianal area includes lichen sclerosus et
atrophicus, irritant dermatitis, intertrigo, bullous
lichen planus, and immunobullous diseases, such
as pemphigus vulgaris and epidermolysis bullosa
acquisita. The clinical course, histology, and immu-
nofluorescence studies help differentiate among
these entities. In this case, the original DIF result of
the perianal eruption was negative, possibly because
of concomitant use of topical corticosteroids. Repeat
DIF after a period of nonsteroid use is indicated if BP
is suspected and the initial DIF result is negative.
TNF-a inhibitors have been used for the treatment
of autoimmune bullous diseases; however, there
are rare reports of paradoxical development of
pemphigus and BP during antieTNF-a therapy.5-10In each of these cases, BP developedmonths to years
after initiation of TNF-a inhibitor treatment, in
contrast to this case in which localized BP general-
ized immediately after administration of an
antieTNF-a agent. In our case, a causal relationship
between etanercept and generalized BP is supported
by the onset of generalization immediately after
etanercept administration and improvement of the
eruption after discontinuation of the drug.
Furthermore, this finding is supported by similar
reports in the literature.5,10 Case reports of
pemphigus and BP induced by TNF-a inhibitors
indicate that patients achieved both clinical and
serologic remission after cessation of the TNF-a
inhibitor. In a case of etanercept-induced BP, the
presence of circulating autoantibodies against the
BP180 antigen decreased into the normal range after
removal of the offending biologic drug.10 Similarly,
Boussemart et al8 reported a case of infliximab-
associated pemphigus foliaceus with normalization
of antidesmoglein 1 autoantibodies after cessation
of infliximab therapy. Rechallenge in select
patients resulted in re-emergence of pemphigus/
pemphigoid.6,10
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induced BP has yet to be deciphered, although
several hypotheses exist. TNF-a appears to play an
important role in BP, as abnormal levels of TNF-a
have been identified in the serum and blister fluid
of patients, and serum TNF-a levels correlate with
disease severity.8 Liu et al11 found that TNF-a can
drive eosinophils to secrete either helper T cell
(Th)1 or Th2 cytokines, depending on the chemo-
kine profile of the microenvironment.11 Thus, an
individual’s unique inflammatory state may affect
the downstream consequences of TNF-a inhibition
and can explain the ability of anti-TNF agents to
both treat and promote BP. TNF-a inhibitors may
also alter the regulatory T-cell function, leading to
loss of B-cell suppression and promotion of
autoantibody production. Another theory is that
TNF-a inhibitors may act as haptens that alter
basement membrane proteins and render them
susceptible to immune attack.12 In this case, it is
possible that exposure of the BP180 antigen or the
inflammatory microenvironment in the eroded
anogenital plaques may have hastened the
immune response generated by etanercept,
resulting in almost immediate generalization.
Further studies are needed to better elucidate the
mechanism of action of TNF-a inhibitors and to
determine how the cytokine milieu may affect
TNF-induced alterations in Th1/Th2 balance.
This case highlights that treatment with TNF-a
inhibitors can be associated with generalization of
localized BP. Caution should be exercised when
contemplating antieTNF-a therapy for the treatment
of autoimmune bullous disorders. Additionally,
TNF-a inhibitors should be considered in the
etiologies of autoimmune bullous disease.REFERENCES
1. della Torre R, Combescure C, Cortes B, et al. Clinical
presentation and diagnostic delay in bullous pemphigoid: a
prospective nationwide cohort. Br J Dermatol. 2012;167:
1111-1117.
2. Ramos-Casals M, Brito-Zeron P, Soto MJ, Cuadrado MJ,
Khamashta MA. Autoimmune diseases induced by
TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008;
22:847-861.
3. Patsatsi A, Lazaridou E, Papagaryfallou I, Sotiriadis D.
Bullous pemphigoid of the perineum and perianal area:
a rare localized form in adults. Acta Derm Venereol. 2008;
88:401.
4. Farrell AM, Kirtschig G, Dalziel KL, et al. Childhood vulval
pemphigoid: a clinical and immunopathological study of five
patients. Br J Dermatol. 1999;140:308-312.
5. Bordignon M, Belloni-Fortina A, Pigozzi B, Tarantello M,
Alaibac M. Bullous pemphigoid during long-term TNF-alpha
blocker therapy. Dermatology. 2009;219:357-358.
6. Daulat S, Detweiler JG, Pandya AG. Development of
pemphigus vulgaris in a patient with psoriasis treated with
etanercept. J Eur Acad Dermatol Venereol. 2009;23:483-484.
7. Stausbøl-Grøn B, Deleuran M, Sommer Hansen E, Kragballe K.
Development of bullous pemphigoid during treatment of
psoriasis with adalimumab. Clin Exp Dermatol. 2009;34:
e285-e286.
8. Boussemart L, Jacobelli S, Batteux F, et al. Autoimmune
bullous skin diseases occurring under anti-tumor necrosis
factor therapy: two case reports. Dermatology. 2010;221:
201-205.
9. Kluk J, Goulding JM, Bhat J, Finch TM. Drug-induced bullous
pemphigoid: cases triggered by intravenous iodine and
etanercept. Clin Exp Dermatol. 2011;36:871-873.
10. Mochizuki M, Fujine E, Tawada C, Kanoh H, Seishima M.
Pemphigoid nodularis possibly induced by etanercept. J
Dermatol. 2013;40:578-579.
11. Liu LY, Bates ME, Jarjour NN, Busse WW, Bertics PJ, Kelly EA.
Generation of Th1 and Th2 chemokines by human eosinophils:
evidence for a critical role of TNF-alpha. J Immunol. 2007;179:
4840-4848.
12. Stavropoulos PG, Soura E, Antoniou C. Drug-induced
pemphigoid: a review of the literature. J Eur Acad Dermatol
Venereol. 2014;28:1133-1140.
